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 SUMMARY STATEMENT 
This work identifies a molecular mechanism that controls the onset of mitotic cell death, 
which is important for surveillance against defects in mitosis and the response to cancer 
drugs that target cell division. 
 
ABSTRACT 
Regulation of cell death is critical for the response of cancer cells to drug treatments that 
cause arrest in mitosis, and is likely to be important for protection against chromosome 
instability in normal cells. Prolonged mitotic arrest can result in cell death by activation of 
caspases and the induction of apoptosis. Here, we show that X-linked inhibitor of apoptosis 
(XIAP) plays a key role in the control of mitotic cell death. Ablation of XIAP expression 
sensitises cells to prolonged mitotic arrest caused by a microtubule poison. XIAP is stable 
during mitotic arrest, but its function is controlled through phosphorylation by the mitotic 
kinase CDK1-cyclin B1 at Ser40. Mutation of Ser40 to a phospho-mimetic residue (S40D) 
inhibits binding to activated effector caspases and abolishes the anti-apoptotic function of 
XIAP, whereas a non-phosphorylated mutant (S40A) blocks apoptosis. By live-cell imaging, 
we show that phosphorylation of XIAP reduces the threshold for the onset of cell death in 
mitosis. This work illustrates that mitotic cell death is a form of apoptosis linked to the 
progression of mitosis through control by CDK1-cyclin B. 
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 INTRODUCTION 
Anti-cancer drugs such as microtubule poisons arrest or delay cells in mitosis due to the 
action of the mitotic or spindle assembly checkpoint. This checkpoint normally prevents 
anaphase from occurring before all chromosomes are correctly bi-orientated on the 
metaphase spindle by inhibition of the anaphase-promoting complex or cyclosome (APC/C), 
a large E3 ubiquitin ligase complex that targets mitotic regulators such as securin and cyclin 
B1 for destruction by the proteasome (Primorac and Musacchio, 2013). Cells that are arrested 
for a prolonged period in mitosis can undergo cell death by the process of apoptosis (Allan 
and Clarke, 2007; Gascoigne and Taylor, 2008). The propensity for apoptosis is increased by 
the duration of the mitotic arrest (Bekier et al., 2009; Huang et al., 2009) whereas exit from 
mitosis generally reduces sensitivity to anti-mitotic drugs (Brito and Rieder, 2006; Gascoigne 
and Taylor, 2008). Apoptosis can still occur after release from a prolonged delay in mitosis 
after longer-term changes including activation of signalling pathways and new protein 
expression (Colin et al., 2015; Uetake and Sluder, 2010). 
The intrinsic apoptotic pathway is activated when cytochrome c is released from 
mitochondria into the cytosol, where it forms a complex with Apaf-1 leading to the 
recruitment and activation of caspase-9, a cystyl-aspartame endoprotease. Caspase-9 in turn 
cleaves and activates the effector caspases -3 and -7, which act on multiple substrates to bring 
about the cellular changes associated with apoptosis, including cellular blebbing, chromatin 
condensation and internucleosomal DNA fragmentation (Budihardjo et al., 1999). This 
pathway is controlled during mitosis by protein phosphorylation and the 
ubiquitin/proteasome-mediated destruction of regulators of the intrinsic apoptotic pathway; 
these mechanisms couple the control of apoptosis to the progression of mitosis (Clarke and 
Allan, 2009). Caspase-9 is phosphorylated at an inhibitory site in mitosis by CDK1-cyclin 
B1, the major mitotic protein kinase, which thereby restrains apoptosis during normal mitosis 
and the initial stages of mitotic arrest. If metaphase is not successfully resolved then 
apoptosis is initiated during a prolonged mitotic arrest when the apoptotic signal overcomes 
the threshold set by caspase-9 phosphorylation (Allan and Clarke, 2007). Conversely, the 
apoptotic signal is initiated when phosphorylation of the anti-apoptotic protein Mcl-1 at 
Thr92 by CDK1-cyclin B1 causes it to be degraded during a delay in mitosis (Harley et al., 
2010; Wertz et al., 2011). Stabilisation of Mcl-1 by abolition of Thr92 phosphorylation or 
mutation of a destruction box (D-Box) that is recognised by the APC/C inhibits apoptosis 
induced by microtubule poisons (Harley et al., 2010). In addition, the related anti-apoptotic 
proteins Bcl-2 and Bcl-xL are phosphorylated and appear to be partially inhibited during 
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 mitosis (Terrano et al., 2010). The slow degradation of cyclin B1 even though the spindle 
assembly checkpoint is active can lead eventually to inactivation of CDK1-cyclin B1 and 
slippage out of mitosis (Brito and Rieder, 2006). Whether or not apoptosis is initiated during 
mitotic arrest is likely to depend upon relative changes in the activities of CDK1-cyclin B1 
and regulators of apoptosis during the mitotic arrest (Allan and Clarke, 2007; Gascoigne and 
Taylor, 2008).  
Although caspase-3 and caspase-7 do not appear to be regulated directly during 
mitosis by phosphorylation, these enzymes might also be controlled through interacting 
proteins. One candidate is XIAP (X-linked inhibitor of apoptosis), a protein of the IAP family 
that is capable of inhibiting activated caspases-3, -7 and -9 by direct binding (Deveraux et al., 
1999; Takahashi et al., 1998). XIAP can also function as an E3 ubiquitin ligase and as a 
signal transduction intermediate (Eckelman et al., 2006; Lu et al., 2007). XIAP is over-
expressed in a number of cancer cell lines and its over-expression correlates with increased 
resistance to chemotherapeutic drugs, including inhibitors of mitosis (Durie et al., 2011; 
Holcik et al., 2000; Tamm et al., 2000).  
XIAP is regulated acutely by post-translational modifications that can determine 
sensitivity to cellular stresses: phosphorylation at serine 87 by Akt reduces XIAP auto-
ubiquitylation and stabilises the protein in cisplatin-treated cells (Dan et al., 2004) whereas 
phosphorylation at serine 430 by TANK-binding kinase 1 (TBK1) or I B kinase IKK  results 
in the auto-ubiquitylation and subsequent proteasomal degradation of XIAP after viral 
infection of cells (Nakhaei et al., 2012). However, it has been unclear if regulation of XIAP 
plays a role in controlling apoptosis during mitosis. In this study, we show that XIAP is 
phosphorylated at specific sites during mitosis by CDK1-cyclin B, which inhibits the anti-
apoptotic activity of XIAP and makes mitotic cells more sensitive to pro-apoptotic signals. 
Thus, XIAP plays a key role in coupling the control of apoptosis to the progression of 
mitosis.  
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 RESULTS 
 
XIAP restrains apoptosis in response to prolonged mitotic arrest 
We tested the role of human XIAP in the control of apoptosis in response to the disruption of 
mitosis. We found that ablation of XIAP in U2OS cells by siRNA promoted the cleavage and 
activation of caspase-3, a major effector of apoptosis (Figure 1A,B; Supplementary figure 
1A), and caused sub-G1 apoptotic fragmentation of DNA (Figure 1C; Supplementary figure 
1B) after prolonged treatment of the cells with nocodazole, a microtubule poison that 
prevents mitotic spindle assembly and arrests cells in mitosis. Entirely consistent with these 
results, there was increased active caspase-3 and sub-G1 DNA fragmentation in XIAP-/- 
HCT116 cells compared to wild-type cells after prolonged treatment with nocodazole 
(Supplementary figure 1C,D). Thus, XIAP plays a role in the restraint of apoptosis in 
response to prolonged mitotic arrest. 
 
XIAP is phosphorylated during mitosis 
Although these results established that XIAP plays a role in the control of apoptosis in 
response to prolonged mitotic arrest, we did not observe any periodic changes in the levels of 
the protein during the cell cycle (Supplementary figure 2A), which might indicate a 
mechanism of regulation. Similarly, the level of XIAP was maintained during a prolonged 
mitotic arrest until exit from mitosis and the induction of apoptosis (Supplementary figure 
2B). To determine if XIAP is regulated post-translationally by phosphorylation during 
mitosis, we treated HeLa and U2OS cells with nocodazole and compared isolated rounded-up 
mitotic cells with adherent interphase cells. Modification of XIAP leading to retardation of 
the protein was not readily detected on Western blots of conventional SDS-PAGE gels 
(Figure 2A). However, modification of XIAP in mitotic cells was clearly apparent when gels 
were supplemented with PhosTag, an acrylamide-bound ligand that preferentially retards the 
migration of phosphorylated proteins (Kinoshita et al., 2006). There was one major and one 
minor retarded form of XIAP in rounded-up mitotic cells, but not in adherent interphase cells 
also treated with nocodazole nor in untreated asynchronous cells, demonstrating that XIAP 
was phosphorylated on at least two sites specifically during mitosis, with one site 
predominating (Figure 2A). XIAP was also phosphorylated in mitotic HCT116 and DLD1 
human colorectal cancer cells with a very similar pattern of phosphorylated forms (Figure 
2B).  
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  The mitotic phosphorylation of XIAP was reversed in parallel with cyclin B 
degradation when U2OS cells were released from mitotic arrest by washing out nocodazole. 
Dephosphorylation of XIAP was prevented by the proteasome inhibitor MG132, which 
prevents the degradation of cyclin B even in the absence of the checkpoint signal and 
maintains cells in mitosis (Figure 2C). When mitotically-arrested cells were maintained in 
nocodazole having been synchronised in the period of the arrest, phosphorylated forms of 
XIAP progressively accumulated over 2-6 hours. MG132 did not alter the pattern of 
phosphorylated forms during mitotic arrest, indicating that both hypo- and hyper-
phosphorylated XIAP were stable during the period of arrest (Figure 2D).  
 Purified recombinant XIAP expressed as a fusion protein with glutathione-S-
transferase (GST-XIAP) was also phosphorylated in a mitotic HeLa cell extract, with one 
major retarded form observed on PhosTag gels that accumulated over 30 mins (Figure 2E). 
Formation of phosphorylated XIAP form was inhibited by calf intestinal phosphatase (CIP) 
or inhibition of cyclin-dependent kinases (CDKs) by purvalanol A (PA) (Figure 2F), 
indicating mitotic phosphorylation of this major site is dependent on CDK1 in complex with 
cyclin B rather than cyclin A, which is lost from mitotically-arrested cells prior to preparation 
of the extract.  
 
Identification of sites of mitotic phosphorylation in XIAP 
Human XIAP contains four serine/threonine residues (Ser40, Ser87, Thr180 and Thr359) that 
are followed immediately by a proline residue, a characteristic of phosphorylation sites 
targeted by proline-directed kinases such as CDK1-cyclin B. Ser40 has been identified in a 
global analysis of phosphorylation sites (Mertins et al., 2013) and Ser87 has been shown to 
be phosphorylated by Akt (Dan et al., 2004). To analyse these potential mitotic 
phosphorylation sites, we mutated each residue to a non-phosphorylatable alanine residue and 
produced the resulting proteins by in vitro transcription and translation (IVT) in mammalian 
reticulocyte lysate. When incubated in mitotic HeLa cell extract, the wild-type, S87A, T180A 
and T359A proteins were all phosphorylated whereas mutation of Ser40 abolished the 
formation of the predominant phosphorylated form (Figure 3A), indicating that this residue 
was the major phosphorylation site. 
 In another approach to determine the site(s) of mitotic phosphorylation, XIAP stably 
expressed as a fusion with green fluorescent protein (GFP-XIAP) was immunoprecipitated 
from mitotic nocodazole-treated U2OS cells. We confirmed that the protein was indeed 
phosphorylated in mitosis, exhibiting one major and one minor phosphorylated form (Figure 
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 3B), before analysis of tryptic peptides by nano LC-MS/MS on a LTQ-Obitrap Velos mass 
spectrometer in combination with a neutral loss scan on a 4000 QTRAP mass spectrometer to 
detect phosphorylated peptides. Two phosphorylation sites were identified, with a major 
peptide phosphorylated on Ser40 and a less abundant peptide phosphorylated on Thr180 
(Figure 3C). Taking into account the proportion of modified XIAP detected on PhosTag gels, 
this data shows that approximately 50% of XIAP is phosphorylated at Ser40 in cells arrested 
in mitosis, with additional phosphorylation at T180 at a lower stoichiometry. 
 
XIAP is phosphorylated at serine 40 in mitosis 
To facilitate analysis of the phosphorylation of Ser40 in XIAP, a specific polyclonal antibody 
was raised by inoculation with a synthetic peptide that included the phosphorylated site. 
Antibodies were purified from serum by negative selection against the dephosphorylated 
peptide followed by positive selection against the phosphopeptide. Selectivity was tested on 
dot blots where BSA-conjugated peptides were probed using purified antibodies (Figure 4A). 
The pS40 antibody detected IVT XIAP phosphorylated in mitotic HeLa cell extracts, whereas 
the S40A mutant was not detected. Thus, the antibody is specific for phosphorylated Ser40 
and no other phosphorylation site in XIAP (Figure 4B). Endogenous XIAP phosphorylated 
on Ser40 was detected in U2OS cells arrested in mitosis with nocodazole; the specific 
polypeptide was identified by its ablation by prior depletion of XIAP by siRNA transfection 
(Figure 4C).  
We confirmed that Ser40 was phosphorylated in GFP-XIAP expressed in U2OS cells 
arrested in mitosis with nocodazole. Analysis of the migration of GFP-XIAP on PhosTag gels 
(Figure 4D) showed that mutation of Ser40 inhibited the formation of not only the major 
phosphorylated form but also other minor phosphorylated forms. This indicates that Ser40 is 
necessary for phosphorylation at one or more less abundant sites, most likely including 
Thr180. GFP-XIAP was phosphorylated on Ser40 in mitotic U2OS cells but not in untreated 
adherent interphase cells or nocodazole-treated adherent cells (Figure 4E). We unequivocally 
identified this phosphorylated form as GFP-XIAP by its immunoprecipitation from cell 
extracts prior to Western blotting (Figure 4F). 
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 XIAP is phosphorylated at serine 40 by CDK1-cyclin B 
The previous observation that purvalanol A inhibited the phosphorylation of GST-XIAP in 
mitotic HeLa cell extract (Figure 2F) indicated that phosphorylation was dependent on a 
CDK1-cyclin B. Similarly, phosphorylation of IVT XIAP incubated in mitotic HeLa cell 
extract and analysed on a PhosTag gel (Figure 5A) was inhibited by purvalanol A and 
RO3306, a more selective inhibitor that specifically targets CDK1 and not DYRK1A at the 
concentration used (Vassilev et al., 2006). We confirmed that CDK inhibitors, but not other 
kinase inhibitors including wortmannin, inhibited the phosphorylation of Ser40 in XIAP in 
mitotic extracts (Figure 5B). Futhermore, XIAP was phosphorylated on Ser40 in a time-
dependent manner by incubation with purified CDK1-cyclin B1 (Figure 5C), showing that 
this kinase catalyses the phosphorylation of XIAP directly. 
 
Mutation of serine 40 to aspartate inhibits XIAP binding to active effector caspases. 
XIAP is perhaps best known for its ability to bind to and inhibit activate caspases (Deveraux 
et al., 1999; Takahashi et al., 1998). To test whether mitotic phosphorylation of XIAP at 
Ser40 could affect this function we carried out an in vitro binding assay utilising a potentially 
phosphomimetic aspartate mutant (S40D) as a surrogate for phosphorylated XIAP and 
comparing its ability to bind cleaved effector caspases with that of the non-phosphorylatable 
mutant S40A. GFP-XIAP S40D and S40A proteins produced in stably transfected U2OS 
cells were incubated with HeLa cell extract (S100) pretreated with cytochrome c and dATP 
to generate cleaved caspases (Li et al., 1997). Western blotting analysis of proteins co-
precipitating from the extract demonstrated that XIAP S40D was less efficient at binding to 
cleaved caspase 7 and cleaved caspase 3 than the S40A protein (Figure 6). In contrast, both 
XIAP proteins exhibited a similar ability to bind to Smac, a protein that binds to and 
neutralises XIAP function (Du et al., 2000; Verhagen et al., 2000). This shows that the S40D 
protein is competent for some aspects of XIAP function but is inhibited in its ability to bind 
activated effector caspases, indicating that mitotic phosphorylation of XIAP at Ser40 
restrains its ability to inhibit caspase activity. 
 
Modification of XIAP at serine 40 inhibits its anti-apoptotic activity 
The inhibitory effect of the S40D mutation on the ability of XIAP to bind active caspases 
strongly suggests that phosphorylation of Ser40 in XIAP regulates its anti-apoptotic activity. 
To test this possibility, we first characterised the stability of wild type and phosphorylation 
site mutant GFP-XIAP proteins during interphase and mitotic arrest. We found that GFP-
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
dv
an
ce
 a
rt
ic
le
 XIAP S40A and S40D proteins, like the wild-type protein, were expressed at a constant level 
during mitotic arrest, indicating that the stability of the protein during mitosis was not 
affected by phosphorylation at this site (Figure 7A). Consistent with results discussed above 
(Figure 2D), phosphorylation of Ser40 detected by the specific antibody gradually increased 
over 2-6h of arrest (Supplementary figure 3). Importantly, while expression of either wild-
type XIAP or the S40A mutant strongly inhibited the induction of apoptosis after prolonged 
treatment with nocodazole, the S40D mutant was much less effective and produced no 
apparent inhibition of apoptosis (Figure 7B, Supplementary figure 4A). The difference 
between the S40A and S40D proteins strongly suggests that phosphorylation of Ser40 
inhibits the anti-apoptotic activity of XIAP. The similar effect of wild-type and S40A XIAP 
expression is consistent with the dominant inhibitory activity of the non-phosphorylated 
protein which is strongly elevated in both cases.  
 To determine if modification of XIAP at Ser40 affects the acute apoptotic response 
during mitosis when phosphorylation occurs, we analysed the induction of cell death in 
individual mitotic cells by live-cell imaging. U2OS cells arrested in mitosis by 250 ng/ml 
nocodazole were tracked for around 70 h after entry into mitosis, by which time they had 
either slipped from mitosis, blebbing transiently and flattening down as they entered 
interphase (denoted survival), or had undergone rigorous blebbing followed by stasis (mitotic 
cell death) (Figure 7C, Supplementary figure 4B). About 55% of control cells transfected 
with an empty vector (EV) underwent mitotic cell death and cells that expressed S40D 
mutant of XIAP showed only a slight reduction in cell death to 40% of control. By contrast, 
cells expressing either wild-type of S40A mutant of XIAP showed a strong reduction in 
mitotic cell death (<5% of control) (Figure 7D), indicating that phosphorylation of XIAP at 
Ser40 inhibits its activity during mitosis and promotes mitotic cell death. 
 
DISCUSSION 
The induction of apoptosis during mitosis provides a mechanism to selectively kill rogue 
cells that have failed to undergo chromosome segregation successfully and on schedule. This 
pathway also provides opportunities for the selective killing of cancer cells through drugs that 
interfere with mitosis, including microtubule poisons such as taxanes that prevent the proper 
attachment of chromosomes to spindle microtubules and cause a prolonged arrest in mitosis 
due to the activity of the spindle assembly (mitotic) checkpoint. Importantly, there are 
distinct post-translational mechanisms that control apoptosis during mitosis that facilitate 
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 drug-induced cell killing, perhaps especially in cancer cells that have sustained cellular stress 
but in which apoptosis is actively suppressed.  
In this report we have identified a mechanism that controls the induction of cell death 
in mitotically-arrested cells through a key regulator, XIAP. Our results indicate that 
phosphorylation of XIAP at a single major site by the master mitotic kinase, CDK1-cyclin B, 
negates the ability of XIAP to bind to active effector caspases and thereby reduces the 
threshold for apoptosis (Figure 8). We show that approximately 50% of the endogenous 
XIAP protein is phosphorylated at the inhibitory site, Ser40 (Figure 3), suggesting that the 
remaining protein that is not phosphorylated at this site continues to provide a restraint, albeit 
reduced, so that when XIAP is completely ablated, apoptosis is increased further (Figure 1). 
We propose that this mechanism is important for the control of cell death during mitotic 
arrest, because it reduces a downstream barrier to apoptosis once caspases-3/7 have been 
activated after proteolytic destruction of the upstream regulator, Mcl-1 (Harley et al., 2010; 
Wertz et al., 2011). The time-dependent loss of Mcl-1 releases cytochrome c from 
mitochondria, resulting in a pro-apoptotic signal that overwhelms the brake set by inhibitory 
phosphorylation of caspase-9 (Allan and Clarke, 2007), which is also activated by 
dephosphorylation as mitotic arrest progresses (Harley et al., 2010). The inhibition of XIAP 
function by phosphorylation would make mitotically-arrested cells less resistant to caspase 
activitation and may explain the increased sensitivity of such cells to BH3 mimetics that 
inhibit Mcl-1, Bcl-2 and Bcl-xL (Colin et al., 2015; Shi et al., 2011). If cells survive mitotic 
arrest and are released into interphase, dephosphorylation of XIAP would restore its anti-
apoptotic function and raise again the threshold for apoptosis.  
The sensitisation of mitotically arrested cells to apoptosis can be hypothesised to 
actively remove cells that become severely delayed in mitosis due to problems with 
chromosome segregation, supernumerary centrosomes or even aneuploidy. This would 
provide a mechanism to suppress the propagation of chromosome abnormalities (Figure 8). 
Cancer cells exhibiting such defects, however, have presumably gone through a selection 
crisis in which the mechanism of apoptosis during mitosis is actively supressed. Two levels 
of the pathway at which this might well occur are the over-expression of anti-apoptotic Bcl-2 
family proteins, preventing cytochrome c release and caspase activation, or XIAP over-
expression, blocking the action of caspases. At present it is unclear if aberrant changes in the 
post-translational regulation of these components also contribute to the suppression of mitotic 
cell death in cancer cells, but if this is the case then targeting these mechanisms could 
activate apoptosis particularly well in such stressed cells. 
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 The regulation of XIAP by CDK1-cyclin B illustrates the close integration of the 
control of apoptosis with the progression of mitosis. In addition to XIAP, Mcl-1 is destroyed 
by proteolysis following phosphorylation by CDK1-cyclin B (Harley et al., 2010; Wertz et 
al., 2011), and the related anti-apoptotic proteins Bcl-2 and Bcl-xL may be directly inhibited 
by mitotic phosphorylation (Terrano et al., 2010).  Opposing these pro-apoptotic events, we 
have shown that caspase-9 is inhibited by phosphorylation during normal mitosis and in the 
early stages of mitotic arrest (Allan and Clarke, 2007). The importance of the inhibition of 
XIAP by mitotic phosphorylation might be that it removes a downstream brake on apoptosis, 
resulting in one major point of regulation (caspase-9 activation) that permits the induction of 
apoptosis after a prolonged arrest. Anti-cancer drugs that target mitotic cells appear to exploit 
this mechanism to initiate mitosis by arresting or delaying them in mitosis long enough to 
overcome the temporal restraint to caspase activation. Cells that do not undergo full apoptosis 
from the mitotic state may nevertheless carry a signal caused by caspase-dependent DNA 
damage that can subsequently determine long-term cell fate after release into interphase even 
though a higher threshold for apoptosis has been restored (Colin et al., 2015) (Figure 8). Our 
results further emphasise that cell death during mitosis is a form of caspase-dependent 
apoptosis, albeit one under mitosis-specific post-translational controls.  
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 MATERIALS AND METHODS 
 
Cell culture and cell extracts 
HeLa (Ohio) and U2OS (HTB96) cell lines were obtained from Cancer Research UK 
Laboratories, London, UK. HCT116 parental and XIAP knock-out cell lines were purchased 
from Horizon Discovery Ltd., Cambridge, UK. All cell lines were confirmed as negative for 
mycoplasma infection. Cells were cultured in DMEM (Invitrogen) supplemented with 10% 
(v/v) foetal bovine serum (Biosera) and 1% (v/v) Penicillin-Streptomycin (Invitrogen) at 
37 C and 5% CO2. U2OS cells stably expressing GFP-XIAP proteins were generated by 
transfection with pEGFP-XIAP vector containing a G418 resistance marker. Cells were 
grown for 2-3 weeks with 800 g/ml G418 Geneticin (Invitrogen) and maintained in 400 
g/ml G418. Cell extracts were prepared from mitotic or asynchronous HeLa cells at a 
protein concentration of 6-10 mg/ml in EBS [80 mM -glycerophosphate-HCl (pH 7.2), 20 
mM EGTA-NaOH (pH 8.0), 15 mM MgCl2, 100 mM sucrose, 1 mM DTT, 1 mM PMSF] as 
described previously (Harley et al., 2010). HeLa cell cytosolic S100 extracts were supplied at 
a protein concentration of 8 mg/ml in extract buffer [10mM Hepes-KOH (pH 8.5), 10mM 
KCl, 10mM MgCl2, 0.5mM DTT] (Computer Cell Culture Centre, Mons, Belgium). 
 
XIAP knock down by siRNA 
Four RNA oligonucleotides that made up the siGENOME SMARTpool XIAP siRNA 
(Thermo Fisher Scientific) were tested individually. Two of the four oligonucleotides that 
resulted in the most efficient depletion of XIAP were used together in future experiments. 
The two XIAP siRNA oligos and the luciferase control siRNA were:  
XIAP siRNA 1: 5’-GCA CGG AUC UUU ACU UUG-3’ 
XIAP siRNA 2: 5’-GAA CUG GGC AGG UUG UAG A-3’ 
Luciferase siRNA: 5’-CGU ACG CGG AAU ACU UCG ATT-3’ 
U2OS cells were transfected with the oligos using Lipofectamine 2000 (Invitrogen) and 
incubated for 48h. 250 ng/ml nocodazole was then added for a further 48h as required. 
 
Western blotting 
Antibodies were used as described in Supplementary Table 1. 
 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
dv
an
ce
 a
rt
ic
le
 Generation of a polyclonal antibody specific for XIAP phosphorylated at Ser40 
Rabbits were inoculated with the phosphorylated peptide FANFPSGS*PVSASTL (where S* 
represents the phosphorylated residue) by Moravian Biotechnology. A phospho-specific 
antibody, pS40 XIAP, was purified from the serum obtained after a second inoculation on a 
column of phosphorylated peptide coupled to Reactigel beads (Pierce Biotechnology), eluted 
with 0.1 M Glycine-HCl (pH 2.5) which was neutralised with the addition of 1.5 M Tris-HCl 
(pH 8.5) supplemented with 100 g/ml BSA, 50% glycerol and 0.05% sodium azide, and 
stored at -20 C. 
 Phosphorylated or non-phosphorylated peptide was coupled to immunoglobulin-free 
BSA (Sigma-Aldrich) using 50% (w/v) glutaraldehyde solution (Sigma-Aldrich) diluted in 
PBS. The BSA-conjugated peptide solutions were serially diluted in PBS, spotted onto 
nitrocellulose membrane and air-dried before being incubated in Western blocking buffer. 
They were then incubated with 1:500 diluted phospho-specific antibody overnight at 4 C, 
followed by washes and secondary antibody probing. 
 
Detection of active caspase-3 
Cells on coverslips or glass slides were permeabilised by incubating in ice-cold 80% ethanol 
for 15 minutes, and followed by two washes in PBS. Cells were blocked in 5% BSA/0.2% 
Triton-X-100 in PBS for 20 minutes at room temperature, before they were incubated with 
anti-cleaved caspase-3 antibody (Cell Signalling) at 1:400 dilution in 1% BSA/0.2% Triton-
X-100 in PBS at room temperature for 1 h. After two 5-minute washes with 0.2% Triton-X-
100/PBS on a rotary shaker, cells were incubated with 1:200 diluted TRITC-anti-rabbit 
secondary antibody (Dako) and 250 ng/ml DAPI (Sigma) in 1% BSA/0.2% Triton-X-100 in 
PBS in the dark at room temperature for 1 h. This was followed by two 5 min washes with 
0.2% Triton-X-100/PBS and one 5 min wash with PBS on a rotary shaker. Slides were 
mounted with mounting media (Dako), air dried and kept at 4°C in the dark until viewed 
under the microscope. 
 
Microscopy 
Fixed cells were visualised using Zeiss Axiovert 100 microscope with specific filters for the 
excitation of fluorophores. Images were taken at 63  magnification using Openlab software. 
For live-cell imaging, cells were imaged every 10 min in a heated chamber on a Zeiss 
Axiovert 200M microscope. Images were acquired using a C4742-80-12AG camera 
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 (Hamamatsu) and µmanager software and were processed using ImageJ Fiji. Analysis was 
carried out on cells that were arrested in mitosis for at least 6 h with cell death being defined 
by cell morphology and cessation of movement. 
 
Flow cytometry 
Cells stained with propidium iodide were analysed on a FACS flow cytometer (Becton 
Dickinson) on the FL3 channel. A minimum of 104 cells were analysed for each sample. Data 
were displayed as dot plots and histograms showing the cell cycle phases and subG1 
population using FlowJo software. 
 
GFP-XIAP precipitation from cells 
U2OS cells stably expressing GFP or GFP-XIAP were treated with 100 ng/ml nocodazole for 
17 hours. The asynchronous cells from the untreated plate and the mitotically arrested cells 
from the nocodazole treated plates were washed twice in cold PBS, and lysed in cold GFP 
lysis buffer [10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 5 mM -
glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1 g/ml each of aprotinin, 
leupeptin and pepstatin A, 0.2% CHAPS]. The protein concentration of the lysates was 
adjusted to 1 mg/ml with GFP lysis buffer. 300 g lysate was mixed with 10 l pre-washed 
GFP-Trap beads (ChromoTek) for each sample, and incubated at 4°C for 1 h on a rotator. 
The beads were pelleted by centrifugation at 4°C, washed once with GFP lysis buffer 
followed by two washes with 10 mM Tris-HCl (pH 7.5). Samples were analysed by SDS-
PAGE and Western blotting. 
 
In vitro phosphorylation assays 
 GST-XIAP was expressed from the pGEX-6P-1 vector in E.coli BLR(DE3) competent cells 
(Novagen), purified on Glutathione Sepharose 4B beads (Amersham) and stored in 10 mM 
Hepes-KOH (pH 7.5), 150 mM NaCl, 0.07% -mercaptoethanol. In vitro translated and 
transcribed (IVT) XIAP was produced using the TNT Quick Coupled 
Transcription/Translation system (Promega) using XIAP inserted in the pcDNA3.2/V5-DEST 
vector. Either 50 ng of GST-XIAP or 3 l IVT XIAP was incubated with 1 l mitotic HeLa 
EBS extract in phosphorylation reaction buffer [50 mM Tris-HCl (pH 7.5), 1 mM DTT] plus 
MgATP [0.1 mM ATP, 10 mM MgCl2, 5 mM Hepes-KOH (pH 7.5)] at 30 C for 30 min in a 
total reaction volume of 10 l. For phosphorylation by CDK1-cyclin B1, 25 ng active 
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 recombinant kinase (Millipore) replaced HeLa extract. Where specified, 1 U/ l calf intestinal 
phosphatase (CIP) (Roche) and 1 l of 10  CIP reaction buffer [0.5 M Tris (pH 8.5), 1 mM 
EDTA], 1 l of 10  ATP-regenerating system [0.1 mg/ml creatine kinase, 50 mM creatine 
phosphate], or kinase inhibitors were added. After incubation, reactions were stopped by 
addition of an equal volume of 2  SDS lysis buffer, 5% -ME and 0.05% bromophenol blue. 
Due to the presence of EGTA in the cell extract EBS buffer, which would interfere with 
PhosTag reagent, an equal molar concentration of MnCl2 was added to the loading samples 
that were going to be tested on PhosTag gels. Samples were boiled for 4 min, then analysed 
by SDS-PAGE and Western blotting. 
 
In vitro binding assay 
HeLa S100 extract (4mg) was incubated with 10µM cytochrome c and 1mM dATP together 
with ATP regenerating system (1mM ATP, 10µg/ml creatine kinase, 5mM creatine 
phosphate), 30 C, 3 h. U2OS cells stably expressing GFP-XIAP S40A or S40D were lysed in 
GFP-Trap buffer [10mM Tris (pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.5% NP40]. 2mg 
lysate was diluted 2:3 with dilution buffer (GFP-Trap buffer without NP40) and incubated 
with 25µl GFP-TrapM beads (ChromoTek), 4 C, 1 h with rotation. Beads were isolated using 
a magnet (BioRad) and washed 3 times in GFP-Trap buffer diluted as above followed by one 
wash in dilution buffer. GFP-XIAP beads were then incubated with S100/cytochrome 
c/dATP reactions at room temperature, 90 min with rotation. Beads were then isolated, 
washed as above and boiled in SDS gel-loading buffer. 
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Figure 1. Endogenous XIAP restrains apoptosis in response to mitotic arrest. 
Knock down of endogenous XIAP results in increased caspase-3 activity and apoptois in 
response to prolonged mitotic arrest. U2OS cells were either untrasfected (Unt), transfected 
with siRNA directed against luciferase as control (Luc) or XIAP (siX) for 48 h and then 
either untreated (asynchronous, As) or treated with 250 ng/ml nocodazole for a further 48 h 
(Noc).  
(A,B) Generation of active, cleaved caspase-3 was analysed by (A) SDS-PAGE and Western 
blotting, or (B) fluorescence microscopy. In (B), at least 300 cells were counted for each 
category in every experiment (n=4). Error bars represent ±SD, NS = non-significant 
difference,  *statistically significant difference, P<0.05. 
(C) Apoptosis was analysed by subG1 DNA content by flow cytometry (n=3). Error bars 
represent ±SD, NS = non-significant difference,  *statistically significant difference, P<0.05.  
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Figure 2. XIAP is phosphorylated in mitotically arrested cells. 
(A) Analysis of XIAP phosphorylation on PhosTag gels. HeLa and U2OS cells were 
treated with 100 ng/ml nocodazole for 17 h and harvested as either non-adherent nocodazole 
mitotic (NM) or nocodazole adherent interphase (NAd) samples. Untreated asynchronous 
cells (A) were used as a control. Samples were analysed on SDS-PAGE with or without the 
addition of PhosTag (PT) as indicated. * denotes a non-specific band detected by XIAP 
antibody. 
(B) XIAP is phosphorylated in mitotically arrested cells. U2OS, HCT116 and DLD-1 cells 
were treated with 100 ng/ml nocodazole for 17 h. The non-adherent nocodazole mitotic (M) 
samples were collected, and samples were analysed by SDS-PAGE and Western blotting.  
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 (C) XIAP phosphorylation is mitosis-specific and the protein is dephosphorylated as 
cells exit mitosis. U2OS cells were either untreated (A) or treated with 100 ng/ml nocodazole 
for 17 h before the rounded up cells were either lysed, or replated in nocodazole-free media 
in the absence or presence of 10 μM of the proteasome inhibitor, MG132, for a further 1, 2, 
or 4 h. Samples were analysed by SDS-PAGE with or without the addition of PhosTag as 
indicated, and Western blotting using the indicated antibodies.  
(D) XIAP is continuously phosphorylated during mitosis and the phosphorylated form 
is stable. U2OS cells were either untreated (A) or pre-treated with 10 μM MG132 for 2 h, 
before adding 100 ng/ml nocodazole to the media and leaving for 2 h. The rounded up mitotic 
cells were then isolated, and either lysed or replated in the same media for a further 2 or 4 h. 
The floating cells were collected at the end of the time course. Samples were analysed by 
SDS-PAGE, and immunoblotted with indicated antibodies. 
 (E) Recombinant GST-XIAP is phosphorylated in mitotic cell extract. Asynchronous 
(A) and nocodazole-treated mitotic (M) HeLa cell extracts were incubated with recombinant 
GST-tagged XIAP protein for the indicated time. Reactions were terminated by the addition 
of 2× SDS lysis buffer and samples were analysed by SDS-PAGE and Western blotting.  
(F) Phosphorylation of GST-XIAP is inhibited by a CDK inhibitor or phosphatase.  In 
vitro phosphorylation reaction in mitotic (M) cell extracts was carried out for 30 min in the 
presence of 10 μM purvalanol A (PA), 0.4 U calf intestinal phosphatase (CIP), phosphatase 
buffer (–), ATP-regenerating system (ATP) or both ATP-regenerating system and CIP (A/C). 
Samples were analysed by SDS-PAGE and Western blotting. A lysate prepared from 
untreated asynchronous cells (A) was used as a control. 
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Figure 3. Identification of sites in XIAP phosphorylated in mitosis. 
 (A) In vitro translated (IVT) XIAP is phosphorylated in mitotic cell extract. Wild-type 
(wt) and four mutant XIAP proteins were expressed in vitro to a similar level by IVT and 
added to extracts from asynchronous (A) or mitotically-arrested HeLa cells to a level much 
greater than endogenous XIAP protein. Nocodazole-treated mitotic extract (M) was also 
incubated with wild-type protein in the presence of calf intestinal phosphatase (CIP) or 
phosphatase storage buffer (CIP(-)) to confirm the phosphorylation. Reactions were 
terminated by the addition of 2× SDS lysis buffer, and the samples were analysed by SDS-
PAGE and Western blotting.  
(B,C) GFP-tagged XIAP is mitotically phosphorylated at Ser40. (B) U2OS cells that were 
either untransfected (Unt) or stably expressing GFP-tagged wild-type XIAP (wt) were treated 
with 100 ng/ml nocodazole for 17 h. The floating mitotic cells were collected at the end of 
the treatment and analysed by PhosTag SDS-PAGE and western blotting. (C) GFP-XIAP was 
precipitated from 2.2 mg cell lysate of mitotically arrested U2OS XIAP wild-type cells that 
had been treated with 100 ng/ml nocodazole for 24 h. GFP-XIAP was immunoprecipitated 
using GFP-Trap beads and analysed by mass spectrometry of tryptic peptides. 
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Figure 4. XIAP is phosphorylated at Ser40 in mitotic cells. 
(A) An antibody generated against pS40 XIAP is specific for the phosphopeptide. 
Decreasing amounts of the non-phospho-peptide (NP), phospho-peptide (P) and BSA control 
were spotted onto nitrocellulose membranes. The membranes were immunoblotted with 
1:500 diluted phospho-antibody purified from serum.  
(B) The pS40 antibody specifically recognizes XIAP phosphorylated at Ser40. Wild-type 
(wt) and S40A mutant XIAP protein were generated using IVT, and the reaction mix for each 
protein was incubated with either asynchronous (A) or mitotic arrested (M) HeLa cell extract. 
Samples were analysed by SDS-PAGE and Western blotting. The IVT reaction mix 
incubated without vector DNA was used as an extra negative control (IVT lysate), which 
showed that the non-specific band (*) was a protein present in the reticulocyte lysate that was 
phosphorylated by HeLa mitotic extract. 
(C) Endogenous XIAP is phosphorylated at Ser40 in cells. U2OS cells were transfected 
with siRNA against XIAP or Luciferase (Luc). 48 h post-transfection, cells were either 
untreated (A) or treated with 250 ng/ml nocodazole for 24 h (NM). All cells were collected 
from untreated samples and the floating cells were collected from nocodazole-treated 
samples. Cells were lysed, analysed by SDS-PAGE and immunoblotted with pS40 antibody. 
Phosphorylated XIAP, which is ablated by the specific siRNA, is indicated by an arrow. 
(D-F) Ser40 is required for XIAP phosphorylation in cells. U2OS cells which were 
untransfected (Unt) or stably expressing GFP-XIAP wild-type (wt) or S40A were either 
untreated (A) or treated with 100 ng/ml nocodazole for 17 h. The floating cells were collected 
from nocodazole treated samples. All cell lysates were analysed by SDS-PAGE and 
immunoblotted with indicated antibodies. In (D), samples were analysed on a PhosTag (PT) 
gel. In (E), adherent interphase cells (NAd) from nocodazole treated samples were also 
analysed. In (F), cell lysates were incubated with GFP-Trap beads and GFP-tagged proteins 
were immunoprecipitated from the samples. Lysates which were not incubated with beads 
were used as input samples.  
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Figure 5. XIAP is phosphorylated at Ser40 by CDK1-cyclin B. 
 (A) CDK1 kinase inhibitors suppress phosphorylation of XIAP in vitro. Wild-type XIAP 
produced by coupled in vitro translation/transcription (IVT XIAP) was incubated with 
asynchronous (A) or mitotic nocodazole-treated (M) HeLa cell extracts with or without 
kinase inhibitors purvalanol A (PA, 10 μM) and RO 3306 (RO, 10 μM). Lysates were 
analysed by PhosTag (PT) SDS-PAGE and immunoblotted with XIAP antibody.  
(B) Wild-type (wt) IVT XIAP was incubated with asynchronous (A) or mitotic nocodazole-
treated (M) HeLa cell extracts at 30°C for 30 min with or without kinase inhibitors. 
Wortmannin (W) was used at 0.1 μM. PA and RO as in (A). IVT reticulocyte lysate without 
vector DNA, HeLa extracts incubated alone, IVT lysate without vector DNA incubated with 
HeLa extracts and IVT S40A mutant incubated with HeLa extracts were used as negative 
controls. Reactions were analysed by SDS-PAGE and immunoblotted with pS40 XIAP 
antibody. 
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  (C) Ser40 of XIAP is phosphorylated by CDK1-cyclin B1. Active recombinant GST-
tagged CDK1-cyclin B1 was incubated with two different amounts of wild-type IVT-XIAP at 
30°C over varying times as indicated. IVT XIAP alone, CDK1-cyclin B1 alone, and IVT 
XIAP incubated with HeLa extracts were used as controls. Reactions were stopped by the 
addition of 2× SDS lysis buffer. Samples were analysed by SDS-PAGE and Western blotting. 
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Figure 6. The ability of XIAP to bind cleaved effector caspases is inhibited by mutation 
of Ser 40 to phosphomimetic aspartate. 
HeLa S100 extract was incubated with cytochrome c and dATP to induce caspase cleavage 
prior to incubation with GFP-XIAP precipitated from cells stably expressing GFP-XIAP 
S40A or S40D protein. GFP-XIAP was recovered from the extract and co-precipitating 
proteins were detected by western blotting using the indicated antibodies. Cell lysates and 
HeLa cell S100 reactions were analysed for comparison. 
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Figure 7. Mutation of Ser40 in XIAP to phosphomimetic aspartate inhibits its ability to 
protect cells against apoptosis induced by prolonged mitotic arrest.  
(A,B) Cell death following mitotic arrest is not inhibited by expression of XIAP S40D 
protein. U2OS cells which were untransfected (Unt), stably expressing GFP-tagged wild-
type (wt), S40A or S40D mutant XIAP protein were treated with 250 ng/ml nocodazole for 
48 h. All cells were collected at the end of the time course and either (A) lysed, analysed by 
SDS-PAGE and Western blotting (representative blots are shown) or (B) fixed and stained 
with PI for sub G1 analysis using flow cytometry (n=3). In (B), error bars represent ±SD, NS 
= non-significant difference. Significant difference, **P<0.005. 
(C,D) XIAP S40D fails to restrain apoptosis during mitotic arrest. Cells stably expressing 
GFP-tagged wild-type (wt), S40A or S40D mutant XIAP protein were treated with 250 ng/ml 
nocodazole. Cell fate following mitotic entry was monitored by time-lapse microscopy. (C) 
Representative images of cells expressing S40A or S40D mutant XIAP are shown. Examples 
of cells undergoing slippage (open arrows) or mitotic cell death (full arrows) are indicated. 
Scale bar = 50µm. (D) Quantification of mitotic cell death in cell lines depicted in (C), 
control cells (Ctrl) and cells expressing wild-type XIAP (wt). For each experiment (n=3), the 
fate of 50 cells was assessed. Error bars represent ±SD. NS = non-significant difference. 
Significant differences **P<0.01, ****P<0.0001. 
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Figure 8. Role of XIAP in determining cell fate during mitotic arrest. 
CDK1-cyclin B1 drives cells into mitosis and controls the induction of apoptosis by 
inhibitory phosphorylation of XIAP. After the last unattached kinetochore is correctly 
attached to spindle microtubules and the chromosomes are properly aligned, the spindle 
assembly or mitotic checkpoint (MC) is switched off. CDK1 is then inactivated as cyclin B is 
rapidly degraded, and cells progress through anaphase, undergo cytokinesis and exit mitosis. 
In the presence of an anti-mitotic drug such as a microtubule poison, the checkpoint cannot 
be satisfied and cells are arrested for a prolonged period. Arrested cells may undergo cell 
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 death or can slip out of mitosis due to the slow degradation of cyclin B and undergo a variety 
of alternative cell fates. Phosphorylation of XIAP reduces the threshold for apoptosis during 
mitotic arrest. However, when a cell exits mitosis normally or slips out of mitotic arrest, 
XIAP is reactivated by dephosphorylation and contributes to cell survival. 
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J. Cell Sci. 129: doi:10.1242/jcs.192310: Supplementary information 
Figure S1. XIAP restrains apoptosis in response to prolonged mitotic arrest.  
(A,B) U2OS cells were untransfected (Unt) or transfected with siRNA against luciferase (Luc) or 
XIAP (siX) for 48 h and then treated with 250ng/ml nocodazole for a further 48 h. (A) 
Representative images of cleaved caspase-3 immunofluorescence. DNA was visualised with 
DAPI. Scale bar = 50µm. (B) Cell cycle profile from the flow cytometry analysis of subG1 
population in asynchronous and nocodazole treated cells. The graphs were generated using the 
software FlowJo. Cells were stained with PI and sorted according to their DNA content 
(propidium iodide staining) along the X-axis. Cells with less than 2N DNA content (subG1) were 
considered apoptotic. 
(C,D). Human HCT116 cells which were either wild type (+/+) or XIAP null (-/-), were untreated 
(Unt) or treated with 250 ng/ml nocodozole for 24 (N24h) or 32 h (N32h), after which time all the 
cells on the plate were harvested and analysed. (C) Cells were lysed and analysed by SDS-PAGE 
and immunoblotting with antibodies to XIAP, cleaved (active) caspase-3 and actin as a loading 
control. * Indicates a non-specific band detected by the XIAP antibody. (D) Cells were fixed and 
stained with propidium iodide for analysis of subG1 DNA content using flow cytometry.  
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Figure S2. Level of XIAP does not vary periodically during the cell cycle. 
(A) U2OS cells were synchronised at the G1/S boundary by double thymidine block,
released into fresh media and harvested at the times indicated (0-24h). The approximate
timing of S, G1 and M phases are indicated. Samples were blotted with antibodies as
indicated. Cell lysates from asynchronous (As) and untreated mitotic (M) cells were
used as controls.
(B) U2OS cells were treated with 100 ng/ml nocodazole (Noc) or 100 nM paclitaxel
(Taxol) for 17-48 h and rounded up mitotic and apoptotic cells were collected. A cell
lysate from asynchronous cells (As) was used as a control. Samples were blotted with
antibodies as indicated. Loss of XIAP coincides with exit from mitosis, indicated by
loss of cyclin B1 and phospho-Ser10 Histone H3, and the onset of apoptosis, indicated
by the cleavage of PARP to generate a faster migrating form.
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Figure S3. S40A and S40D mutant XIAP proteins remain stable during a short 
mitotic arrest. Cells stably expressing GFP-tagged wild-type (wt), S40A or S40D 
XIAP were treated with 100 ng/ml nocodazole for 2 h, before the floating population 
was isolated and replated in the same nocodazole-containing media for another 2 or 4 h. 
The nocodazole-treated cells (NM) were analysed alongside untreated asynchronous 
cells (A) by SDS-PAGE, and immunoblotted with XIAP phospho-specific antibody 
pS40 and mitotic markers Cyclin B1 and pS10 H3. 
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Figure S4. Over-expression of S40D XIAP does not protect cells from cell death in a 
prolonged mitotic arrest. 
(A) The cell cycle profile from the flow cytometry analysis of cell death in untransfected or stable
cell lines that were either untreated (asynchronous) or treated with nocodazole. The graphs were
generated using the software FlowJo. Cells were stained with PI and sorted according to their
DNA content along the X-axis. Cells with less than 2N DNA content (SubG1) were considered
apoptotic.
(B) U2OS cells stably expressing GFP-tagged S40A or S40D mutant XIAP protein were treated
with 250ng/ml nocodazole. Cell fate following mitotic entry was followed by time lapse
microscopy. Right hand panels show enlarged images of cells indicated (boxed) in left hand panels
at 24-25 h (S40A) or 41-43 h (S40D). Examples of cells undergoing mitotic slippage (open arrow)
or mitotic cell death (full arrow) are shown. The hatched arrow indicates the residual cell body
following mitotic cell death. Scale bar = 50µm (left hand panels), 10µm (right hand panels).
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Phosphorylation of XIAP by CDK1-cyclin B controls mitotic cell death 
Ying Hou, Lindsey A. Allan and Paul R. Clarke 
Supplementary Table 1. Antibodies 
Primary antibodies 
Primary 
antibody 
Molecular 
weight (kDa) Species 
Dilutions for 
WB/IF Supplier (cat. No.) 
Actin 42 Rabbit 1:5000 Sigma (#A2066) 
Caspase-3 32 Mouse 1:1000 
BD Biosciences 
(#610322) 
Cleaved 
caspase-3 
17 Rabbit 1:1000 
Cell Signalling 
(#9661) 
Cleaved 
caspase-3 
17 Rabbit IF 1:400 
Cell Signalling 
(#9661) 
Caspase-9 47 Mouse 1:1000 Chemicon (MAB4609) 
Cyclin A 60 Mouse 1:1000 
BD Biosciences 
(#611269) 
Cyclin B1 55 Rabbit 1:1000 Santa Cruz (#sc-752) 
GFP 27 Rabbit 1:1000 Santa Cruz (#sc-8334) 
GST 26 Rabbit 1:10000 Santa Cruz (#sc-459) 
pS10 HH3 17 Rabbit 1:2500 Millipore (#09-797) 
PARP 116 Mouse 1:1000 
AbD Serotec 
(MCA1522G) 
XIAP 57 Mouse 1:10000 
BD Biosciences 
(#610762) 
pS40 XIAP 57 Rabbit 1:250 
Described in this 
publication 
Secondary antibodies 
Secondary 
antibody 
Species raised 
in 
Dilutions for 
WB/IF Supplier (cat. No.) 
Anti-mouse-HRP Goat 1:5000 Bio-Rad (#170-6516) 
Anti-rabbit-HRP Goat 1:5000 Bio-Rad (#170-6515) 
Anti-rabbit-TRITC Swine IF 1:200 Dako (#R0156) 
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